These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32880724)

  • 21. Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntington's Disease.
    Horta-Barba A; Martinez-Horta S; Perez-Perez J; Sampedro F; de Lucia N; De Michele G; Salvatore E; Kehrer S; Priller J; Migliore S; Squitieri F; Castaldo A; Mariotti C; Mañanes V; Lopez-Sendon JL; Rodriguez N; Martinez-Descals A; Júlio F; Janurio C; Delussi M; de Tommaso M; Noguera S; Ruiz-Idiago J; Sitek EJ; Wallner R; Nuzzi A; Pagonabarraga J; Kulisevsky J;
    J Huntingtons Dis; 2021; 10(4):459-468. PubMed ID: 34602494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divergent cognitive trajectories in early stage Huntington's disease: A 3-year longitudinal study.
    Martínez-Horta S; Perez-Perez J; Oltra-Cucarella J; Sampedro F; Horta-Barba A; Puig-Davi A; Pagonabarraga J; Kulisevsky J
    Eur J Neurol; 2023 Jul; 30(7):1871-1879. PubMed ID: 36994811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Language disintegration in spontaneous speech in Huntington's disease: a more fine-grained analysis.
    Tovar A; Garí Soler A; Ruiz-Idiago J; Mareca Viladrich C; Pomarol-Clotet E; Rosselló J; Hinzen W
    J Commun Disord; 2020; 83():105970. PubMed ID: 32062158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive decline in prodromal Huntington Disease: implications for clinical trials.
    Paulsen JS; Smith MM; Long JD;
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1233-9. PubMed ID: 23911948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Another Perspective on Huntington's Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD.
    Achenbach J; Saft C
    Brain Sci; 2021 Dec; 11(12):. PubMed ID: 34942923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD).
    Carlozzi NE; Boileau NR; Paulsen JS; Downing NR; Ready R; Perlmutter JS; Cella D; Chou KL; McCormack MK; Barton S; Lai JS
    Qual Life Res; 2020 May; 29(5):1393-1403. PubMed ID: 31853881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validity, diagnostics and feasibility of the Italian version of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.
    Aiello EN; Solca F; Torre S; Lafronza A; Maranzano A; Bonetti R; Scheveger F; Maffi S; Ceccarelli C; Scocchia M; Casella M; Verde F; Migliore S; Silani V; Ticozzi N; Squitieri F; Ciammola A; Poletti B
    Neurol Sci; 2024 Mar; 45(3):1079-1086. PubMed ID: 37770762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential of composite cognitive scores for tracking progression in Huntington's disease.
    Jones R; Stout JC; Labuschagne I; Say M; Justo D; Coleman A; Dumas EM; Hart E; Owen G; Durr A; Leavitt BR; Roos R; O'Regan A; Langbehn D; Tabrizi SJ; Frost C
    J Huntingtons Dis; 2014; 3(2):197-207. PubMed ID: 25062862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiling Social Cognition in Premanifest Huntington's Disease.
    Turner K; Bartlett D; Grainger SA; Eddy C; Reyes A; Kordsachia C; Turner M; Stout JC; Georgiou-Karistianis N; Henry JD; Ziman M; Cruickshank T
    J Int Neuropsychol Soc; 2022 Mar; 28(3):217-229. PubMed ID: 33949297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of neurocognitive disorder in Huntington's disease using the Enroll-HD dataset.
    Sierra LA; Ullman CJ; Baselga-Garriga C; Pandeya SR; Frank SA; Laganiere S
    Front Neurol; 2023; 14():1198145. PubMed ID: 37521291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Speech biomarkers in Huntington's disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages.
    Kouba T; Frank W; Tykalova T; Mühlbäck A; Klempíř J; Lindenberg KS; Landwehrmeyer GB; Rusz J
    Eur J Neurol; 2023 May; 30(5):1262-1271. PubMed ID: 36732902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meaningful and Measurable Health Domains in Huntington's Disease: Large-Scale Validation of the Huntington's Disease Health-Related Quality of Life Questionnaire Across Severity Stages.
    Ho AK; Horton MC; Landwehrmeyer GB; Burgunder JM; Tennant A;
    Value Health; 2019 Jun; 22(6):712-720. PubMed ID: 31198189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.
    Lemiere J; Decruyenaere M; Evers-Kiebooms G; Vandenbussche E; Dom R
    J Neurol; 2004 Aug; 251(8):935-42. PubMed ID: 15316797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease.
    Julayanont P; Heilman KM; McFarland NR
    Mov Disord; 2020 May; 35(5):781-788. PubMed ID: 31922295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring the functional impact of cognitive impairment in Huntington's disease.
    Horta-Barba A; Martínez-Horta S; Pérez-Pérez J; Sampedro F; Puig-Davi A; Pagonabarraga J; Kulisevsky J
    J Neurol; 2022 Jul; 269(7):3541-3549. PubMed ID: 35061089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual tasking impairments are associated with striatal pathology in Huntington's disease.
    Lo J; Reyes A; Pulverenti TS; Rankin TJ; Bartlett DM; Zaenker P; Rowe G; Feindel K; Poudel G; Georgiou-Karistianis N; Ziman MR; Cruickshank TM
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1608-1619. PubMed ID: 32794343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease.
    Andrews SC; Langbehn DR; Craufurd D; Durr A; Leavitt BR; Roos RA; Tabrizi SJ; Stout JC;
    Psychol Med; 2021 Jun; 51(8):1338-1344. PubMed ID: 32063235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington's disease.
    Murueta-Goyena A; Del Pino R; Acera M; Teijeira-Portas S; Romero D; Ayala U; Fernández-Valle T; Tijero B; Gabilondo I; Gómez Esteban JC
    J Neurol; 2023 Aug; 270(8):3821-3829. PubMed ID: 37079031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual Task Performance May be a Better Measure of Cognitive Processing in Huntington's Disease than Traditional Attention Tests.
    Vaportzis E; Georgiou-Karistianis N; Churchyard A; Stout JC
    J Huntingtons Dis; 2015; 4(2):119-30. PubMed ID: 26397893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.